Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Share-based Compensation: 2009-2024

Historic Share-based Compensation for Gyre Therapeutics (GYRE) over the last 16 years, with Dec 2024 value amounting to $831,000.

  • Gyre Therapeutics' Share-based Compensation rose 383.97% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.1 million, marking a year-over-year decrease of 56.25%. This contributed to the annual value of $831,000 for FY2024, which is 88.59% down from last year.
  • Latest data reveals that Gyre Therapeutics reported Share-based Compensation of $831,000 as of FY2024, which was down 88.59% from $7.3 million recorded in FY2023.
  • Gyre Therapeutics' 5-year Share-based Compensation high stood at $13.4 million for FY2022, and its period low was $831,000 during FY2024.
  • For the 3-year period, Gyre Therapeutics' Share-based Compensation averaged around $7.2 million, with its median value being $7.3 million (2023).
  • Its Share-based Compensation has fluctuated over the past 5 years, first soared by 292.54% in 2022, then slumped by 88.59% in 2024.
  • Gyre Therapeutics' Share-based Compensation (Yearly) stood at $3.6 million in 2020, then decreased by 6.12% to $3.4 million in 2021, then surged by 292.54% to $13.4 million in 2022, then plummeted by 45.53% to $7.3 million in 2023, then tumbled by 88.59% to $831,000 in 2024.